scholarly journals Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pARser81 and CDK1 signaling: biological implications for men treated with testosterone replacement therapy

Oncotarget ◽  
2017 ◽  
Vol 8 (69) ◽  
pp. 113792-113806 ◽  
Author(s):  
Giovanni Luca Gravina ◽  
Francesco Marampon ◽  
Patrizia Sanità ◽  
Claudio Festuccia ◽  
Chiara Forcella ◽  
...  
2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Giacomo Tirabassi ◽  
Nicola delli Muti ◽  
Giovanni Corona ◽  
Mario Maggi ◽  
Giancarlo Balercia

Aim. To evaluate the independent role of androgen receptor (AR) gene CAG repeat polymorphism on metabolic effects of testosterone replacement therapy (TRT) in male postsurgical hypogonadotropic hypogonadism, a condition frequently associated with hypopituitarism and in which the TRT-related metabolic effects are combined with those deriving from concomitant administration of metabolically active pituitary-function replacement therapies.Methods. 15 men affected by postsurgical hypogonadotropic hypogonadism were evaluated before and after TRT. Cardiovascular risk factors (CVRFs), pituitary-dependent hormones, and AR gene CAG repeat polymorphism were considered.Results. Testosterone, insulin-like growth factor 1 (IGF-1), and estradiol were the only hormones, which varied significantly between the two phases. All CVRFs significantly improved after TRT. The number of CAG triplets was positively and significantly correlated with all the variations (Δ-) of CVRFs (except for a significant negative correlation with Δ-high-density lipoprotein); the opposite occurred between the latter and Δ-testosterone. No correlation between Δ-IGF-1 or estradiol and Δ-CVRFs was found. At multiple linear regression, after correction for Δ-testosterone, nearly all the associations between the number of CAG triplets and Δ-CVRFs were confirmed.Conclusions. In male postsurgical hypogonadotropic hypogonadism, shorter AR gene CAG tract length seems to yield greater metabolic improvement after TRT, independently of the effects of concomitant pituitary-function replacement therapies.


2006 ◽  
Vol 39 (13) ◽  
pp. 16
Author(s):  
WILLIAM E. GOLDEN ◽  
ROBERT H. HOPKINS

Author(s):  
Yavor Assyov ◽  
Antoaneta Gateva ◽  
Vera Karamfilova ◽  
Iveta Nedeva ◽  
Tsvetan Gatev ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document